Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,242
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
stocks
Why stocks sometimes fall for no obvious reason
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,904.40 | 25.90 | 0.29% |
| CAC 40 | 8,173.11 | 85.15 | -1.03% |
| DAX 40 | 25,184.89 | 204.21 | -0.80% |
| Dow JONES (US) | 50,461.68 | 118.02 | -0.23% |
| FTSE 100 | 10,491.39 | 25.13 | 0.24% |
| HKSE | 25,416.92 | 182.53 | -0.71% |
| NASDAQ | 26,656.18 | 312.21 | 1.19% |
| Nikkei 225 | 65,816.62 | 820.53 | 1.26% |
| NZX 50 Index | 13,181.45 | 111.71 | 0.85% |
| S&P 500 | 7,519.12 | 45.65 | 0.61% |
| S&P/ASX 200 | 8,673.40 | 21.20 | 0.25% |
| SSE Composite Index | 4,122.21 | 23.17 | -0.56% |